Bryan Smithson, MD
Family Medicine · Show Low, AZNPI 1336377464
Payments from drug & device makers
Across 103 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$261
- Novo Nordisk$256
- GSK$153
- Grifols USA, LLC$152
- Lilly USA, LLC$129
- E.r. Squibb & Sons, L.L.C.$121
- plus $747 from 16 others
What the payments were for
- Food & beverage$1,819100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 16 | $261 |
| Novo Nordisk | 14 | $256 |
| GSK | 10 | $153 |
| Grifols USA, LLC | 7 | $152 |
| Lilly USA, LLC | 8 | $129 |
| E.r. Squibb & Sons, L.L.C. | 6 | $121 |
| AstraZeneca | 8 | $117 |
| Bayer | 7 | $107 |
| Amgen | 4 | $76 |
| Boehringer Ingelheim | 3 | $71 |
| Sumitomo Pharma America, Inc. | 3 | $58 |
| Astellas Pharma US Inc | 3 | $51 |
| Exact Sciences | 2 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Merck | 2 | $41 |
| Insulet Corporation | 1 | $28 |
| Johnson & Johnson | 2 | $25 |
| Biohaven Pharmaceuticals, Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $19 |
| AbbVie | 1 | $15 |
| Medtronic | 1 | $14 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
How this compares
$1,819 in reported general payments places this provider in the 80th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $140,413 |
| EliquisApixaban | 105 | $112,029 |
| RybelsusSemaglutide | 27 | $59,524 |
| JardianceEmpagliflozin | 38 | $46,516 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $34,945 |
| TrulicityDulaglutide | 20 | $20,422 |
| FarxigaDapagliflozin Propanediol | 18 | $18,630 |
| JanuviaSitagliptin Phosphate | 12 | $17,860 |
| OxycontinOxycodone Hcl | 12 | $5,110 |
| PremarinEstrogens, Conjugated | 12 | $5,054 |
| Sumatriptan Succinate | 21 | $5,051 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $4,877 |
| Oxycodone Hcl | 146 | $4,845 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 137 | $4,602 |
| Xtampza ErOxycodone Myristate | 11 | $4,595 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $256 | $199,937134 claims |
| PfizerEliquis, Premarin | $261 | $117,082117 claims |
| Boehringer IngelheimJardiance | $71 | $46,51638 claims |
| GSKTrelegy Ellipta | $153 | $34,94529 claims |
| AstraZenecaFarxiga, Symbicort | $117 | $22,22732 claims |
| Lilly USA, LLCTrulicity | $129 | $20,42220 claims |
| MerckJanuvia | $41 | $17,86012 claims |
| AbbVieSynthroid | $15 | $2,04729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Show Low
- Danielle ArmasScottsdale$73M
- Terry O'ReillyMesa$35.8M
- Shawn SearleChandler$27M
- Corey AndersonMesa$21.5M
- Dena PetersenTucson$14.7M
- Gerald ShockeyMesa$12.3M
- Brock MerrittPhoenix$8.4M
- John McGettiganTucson$8.3M
- Neil ShethChandler$6.7M
- Joseph LilloScottsdale$6.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.